- Home
- PGRE vs CGEM Comparison
PGRE vs CGEM Comparison
Compare PGRE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- CGEM
- Stock Information
- Founded
- PGRE 1978
- CGEM 2016
- Country
- PGRE United States
- CGEM United States
- Employees
- PGRE N/A
- CGEM N/A
- Industry
- PGRE Real Estate Investment Trusts
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- CGEM Health Care
- Exchange
- PGRE Nasdaq
- CGEM Nasdaq
- Market Cap
- PGRE 1.3B
- CGEM 530.0M
- IPO Year
- PGRE 2014
- CGEM 2021
- Fundamental
- Price
- PGRE $6.67
- CGEM $7.68
- Analyst Decision
- PGRE Hold
- CGEM Strong Buy
- Analyst Count
- PGRE 4
- CGEM 6
- Target Price
- PGRE $5.38
- CGEM $28.17
- AVG Volume (30 Days)
- PGRE 3.3M
- CGEM 350.6K
- Earning Date
- PGRE 07-30-2025
- CGEM 08-07-2025
- Dividend Yield
- PGRE N/A
- CGEM N/A
- EPS Growth
- PGRE N/A
- CGEM N/A
- EPS
- PGRE N/A
- CGEM N/A
- Revenue
- PGRE $711,729,000.00
- CGEM N/A
- Revenue This Year
- PGRE $2.74
- CGEM N/A
- Revenue Next Year
- PGRE N/A
- CGEM N/A
- P/E Ratio
- PGRE N/A
- CGEM N/A
- Revenue Growth
- PGRE 49.28
- CGEM N/A
- 52 Week Low
- PGRE $3.75
- CGEM $6.85
- 52 Week High
- PGRE $6.72
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- PGRE 69.05
- CGEM 45.96
- Support Level
- PGRE $5.96
- CGEM $7.29
- Resistance Level
- PGRE $6.72
- CGEM $7.94
- Average True Range (ATR)
- PGRE 0.19
- CGEM 0.39
- MACD
- PGRE 0.00
- CGEM -0.01
- Stochastic Oscillator
- PGRE 86.18
- CGEM 61.01
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.